Rockwell Medical Analyst Ratings
Rockwell Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 285.96% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 07/17/2023 | 285.96% | HC Wainwright & Co. | $9 → $11 | Maintains | Buy |
| 05/30/2023 | 215.79% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 05/02/2023 | 145.61% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/04/2023 | 145.61% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/13/2023 | 145.61% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/08/2023 | 145.61% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 08/30/2022 | 180.7% | HC Wainwright & Co. | $3 → $8 | Maintains | Buy |
| 01/18/2022 | 5.26% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 09/07/2021 | 75.44% | HC Wainwright & Co. | $5.5 → $5 | Maintains | Buy |
| 02/08/2021 | 92.98% | HC Wainwright & Co. | $9 → $5.5 | Maintains | Buy |
| 04/07/2020 | 215.79% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 11/12/2019 | 110.53% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 06/25/2019 | 285.96% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 06/24/2019 | 250.88% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 10/19/2018 | 285.96% | IFS Securities | → $11 | Downgrades | Strong Buy → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/15/2023 | 285.96% | HC Wainwright & Co. | → 11 美元 | 重申 | 購買 → 購買 |
| 07/17/2023 | 285.96% | HC Wainwright & Co. | 9 美元 → 11 美元 | 維護 | 購買 |
| 05/30/2023 | 215.79% | HC Wainwright & Co. | 7 美元 → 9 美元 | 維護 | 購買 |
| 05/02/2023 | 145.61% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 04/04/2023 | 145.61% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 02/13/2023 | 145.61% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 02/08/2023 | 145.61% | HC Wainwright & Co. | 8 美元 → 7 美元 | 維護 | 購買 |
| 08/30/2022 | 180.7% | HC Wainwright & Co. | 3 美元 → 8 美元 | 維護 | 購買 |
| 01/18/2022 | 5.26% | HC Wainwright & Co. | 5 美元 → 3 美元 | 維護 | 購買 |
| 09/07/2021 | 75.44% | HC Wainwright & Co. | 5.5 美元 → 5 美元 | 維護 | 購買 |
| 02/08/2021 | 92.98% | HC Wainwright & Co. | 9 美元 → 5.5 美元 | 維護 | 購買 |
| 2020 年 7 月 4 日 | 215.79% | HC Wainwright & Co. | 11 美元 → 9 美元 | 維護 | 購買 |
| 2019 年 12 月 11 日 | 110.53% | 派珀·桑德勒 | 10 美元 → 6 美元 | 維護 | 超重 |
| 06/25/2019 | 285.96% | 坎託·菲茨傑拉德 | → 11 美元 | 啓動覆蓋開啓 | → 超重 |
| 06/24/2019 | 250.88% | 派珀·桑德勒 | → 10 美元 | 啓動覆蓋開啓 | → 超重 |
| 2018 年 10 月 19 日 | 285.96% | IFS 證券 | → 11 美元 | 降級 | 強勢買入 → 跑贏大盤 |
What is the target price for Rockwell Medical (RMTI)?
羅克韋爾醫療（RMTI）的目標價格是多少？
The latest price target for Rockwell Medical (NASDAQ: RMTI) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting RMTI to rise to within 12 months (a possible 285.96% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月15日公佈了羅克韋爾醫療（納斯達克股票代碼：RMTI）的最新目標股價。這家分析公司將目標股價定爲11.00美元，預計RMTI將在12個月內升至12個月內（可能上漲285.96％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Rockwell Medical (RMTI)?
羅克韋爾醫療（RMTI）的最新分析師評級是多少？
The latest analyst rating for Rockwell Medical (NASDAQ: RMTI) was provided by HC Wainwright & Co., and Rockwell Medical reiterated their buy rating.
Rockwell Medical（納斯達克股票代碼：RMTI）的最新分析師評級由HC Wainwright & Co. 提供，羅克韋爾醫療重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Rockwell Medical (RMTI)?
羅克韋爾醫療（RMTI）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rockwell Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rockwell Medical was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Rockwell Medical的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Rockwell Medical的最後一次評級是在2023年8月15日提交的，因此您應該預計下一個評級將在2024年8月15日左右公佈。
Is the Analyst Rating Rockwell Medical (RMTI) correct?
分析師對羅克韋爾醫療（RMTI）的評級是否正確？
While ratings are subjective and will change, the latest Rockwell Medical (RMTI) rating was a reiterated with a price target of $0.00 to $11.00. The current price Rockwell Medical (RMTI) is trading at is $2.85, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但羅克韋爾醫療（RMTI）的最新評級得到了重申，目標股價爲0.00美元至11.00美元。羅克韋爾醫療（RMTI）目前的交易價格爲2.85美元，在分析師的預測區間內。